Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,408
datasets available to search
ShareScore release 0.9.0
Dataset results
2,408 results for “Atrial fibrillation”
Regional transcriptomics of a human left atrium and implications for atrial fibrillation
GEO Series GSE161450. Homo sapiens. 25 samples. Type: Expression profiling by high throughput sequencing.
Inflammatory and Fibrotic Markers and Atrial Fibrillation
ClinicalTrials.gov study NCT00173589. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A First in Human Evaluation of a Novel Approach to Painless Cardioversion (NAPC) in Patients With Atrial Fibrillation
ClinicalTrials.gov study NCT05324540. IPD Sharing: NO. Countries: 0. Publications: 0.
AtriCure Bipolar Radiofrequency Ablation of Persistent Atrial Fibrillation
ClinicalTrials.gov study NCT00785902. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Comparison of atrial appendage tissues of patients with Valvular Heart Disease and patients with Valvular Heart Disease-Atrial Fibrillation
GEO Series GSE113013. Homo sapiens. 10 samples. Type: Expression profiling by array; Non-coding RNA profiling by array.
Extracellular vesicles from epicardial fat mediate long-distance heart-brain communication and promote atrial fibrillation associated cognitive impairment (EAT exosomal miRNA-seq and hippocampal mRNA-
GEO Series GSE240776. Canis lupus familiaris. 12 samples. Type: Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing.
A microRNA blueprint for early atrial remodeling in a porcine model of paroxysmal atrial fibrilation
GEO Series GSE65330. Sus scrofa. 6 samples. Type: Non-coding RNA profiling by array.
Differential Expression Profiles and Bioinformatics Analysis of tRNA-derived Small RNAs in Epicardial Adipose Tissue of Patients with Atrial Fibrillation
GEO Series GSE210705. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
A reduced TBX5-dependent gene regulatory network links atrial fibrillation and heart failure [Micro-C]
GEO Series GSE311699. Mus musculus. 2 samples. Type: Other.
Gene expression and miRNA profiles in atrial fibrillation. Role of miR-21.
GEO Series GSE31821. Homo sapiens. 6 samples. Type: Expression profiling by array.
Transcriptome analysis from human epicardial adipose tissue biopsies analyzed according to postoperative atrial fibrillation occurrence after cardiac surgery
GEO Series GSE143924. Homo sapiens. 30 samples. Type: Expression profiling by array.
MiR-181b Targets Semaphorin 3a to Mediate TGF-β-induced Endothelial to Mesenchymal Transition: Implication in Atrial Fibrillation
GEO Series GSE156835. Homo sapiens. 6 samples. Type: Expression profiling by array.
Atrial Fibrillation Patient's Urine miRNA Microarray
GEO Series GSE190898. synthetic construct; Homo sapiens. 8 samples. Type: Non-coding RNA profiling by array.
Dataset related to the article "Sex effect on efficacy of pulmonary vein cryoablation in patients with atrial fibrillation: data from the multicenter real-world 1STOP project"
<p>This record contains raw data related to the article "Sex effect on efficacy of pulmonary vein cryoablation in patients with atrial fibrillation: data from the multicenter real-world 1STOP project”</p> <p> </p> <p>ABSTRACT</p> <p>PURPOSE:</p> <p>Pulmonary vein isolation (PVI) using cryoablation (PVI-C) is a widespread therapy for treating symptomatic, recurrent atrial fibrillation (AF). The impacts of sex on efficacy and safety of PVI-C in a real-world clinical practice is lacking. In a multicenter prospective project, we evaluated whether clinical characteristics, procedure parameters, procedural complications, long-term AF recurrence rates, and/or AF-related symptoms differed according to sex in patients treated with PVI-C.</p> <p>METHODS:</p> <p>Data from the study population were collected in the framework of the 1STOP ClinicalService® project, involving 47 Italian cardiology centers. Multivariable statistical analyses were conducted to determine if any baseline clinical characteristics impacted the efficacy of PVI-C.</p> <p>RESULTS:</p> <p>From April 2012, 2125 patients (27% female, 59 ± 11 years, 73% paroxysmal AF, and mean left atrial diameter = 42 ± 8 mm) underwent PVI-C. According to baseline characteristics, women were more likely to be older, with higher clinical risk scores (e.g., CHA<sub>2</sub>DS<sub>2</sub>-VASc), and a higher number of tested antiarrhythmic drugs before the index PVI-C procedure. Male and female cohorts showed comparable procedure time (mean =&thinsp;107.7 ± 46.8 min) and a similar incidence of periprocedural complications (4.5% overall), even after adjustment for baseline characteristics (P =&thinsp;0.880). The multivariable analyses demonstrated that the strongest predictor of AF recurrences was sex (0.74; 95% CI 0.58-0.93; P =&thinsp;0.011). After propensity score adjustment, the hazard ratio from a multivariable model, which included age and AF type (persistent) as covariates, was 0.76 (0.60-0.97) (P =&thinsp;0.025).</p> <p>CONCLUSIONS:</p> <p>According to the 1STOP project, in a real-world setting, PVI-C was relatively safe regardless of the patient's sex; however, when considering efficacy of the procedure, female patients had a lower long-term efficacy in comparison to males.</p> <p>CLINICAL TRIAL REGISTRATION: <a href="http://clinicaltrials.gov/show/NCT01007474">NCT01007474</a>.</p> <p> </p> <p> </p> <p> </p>
Dataset related to the article "An Ablation Index Operator-Independent Approach to Improve Efficacy in Atrial Fibrillation Ablation at 24-month Follow-Up: A Single Center Experience"
<p>This record contains raw data related to the article "An Ablation Index Operator-Independent Approach to Improve Efficacy in Atrial Fibrillation Ablation at 24-month Follow-Up: A Single Center Experience"</p> <p>ABSTRACT</p> <p><strong>Purpose: </strong>Since the introduction of catheter ablation as a mainstream treatment for atrial fibrillation (AF), several technical improvements have been put forward. In this contest, Ablation Index (AI) is an accurate ablation quality marker by incorporating power, delivery time, contact force (CF), and catheter stability in a weighted formula. The aim of our study is to evaluate the efficacy of AI-guided AF ablation over 24 month follow-up.</p> <p><strong>Methods: </strong>We evaluated 72 consecutive patients with drug-refractory paroxysmal (66.7%) and early-persistent AF (33.3%) undergoing AI-guided ablation, compared to 72 propensity-matched control patients who underwent CF-guided procedure. All procedures were performed by three skilled operators. Data concerning procedural characteristics and long-term freedom from AF recurrence were analyzed.</p> <p><strong>Results: </strong>At 24-month follow-up, Kaplan-Meier curves of AF recurrence were significantly lower in AI group than in CF group (15.5% vs. 30.6%; p 0.042). These findings were confirmed in a sub analysis regardless of the continued use of antiarrhythmic drugs in the follow-up (42.2% in AI-guided group and 66.7% in CF-guided group, p 0.004). At 24-month follow-up, a positive trend in the decrease of arrhythmia recurrences was observed in AI-guided ablation for all operators.</p> <p><strong>Conclusions: </strong>AI-guided ablation results more effective than CF-guided ablation as demonstrated by a lower incidence of AF recurrences regardless of the use of antiarrhythmic drugs in the follow-up. Each operator seems to improve the long-term success using an AI-guided ablation, thus showing both the efficacy and the reproducibility of this approach.</p> <p> </p>
Dataset related to the article "Cryoablation of Atrial Fibrillation With the Fourth-Generation Balloon: The First Reported Case"
<p>This record contains raw data related to the article "Cryoablation of Atrial Fibrillation With the Fourth-Generation Balloon: The First Reported Case"</p> <p>ABSTRACT</p> <p>Cryoballoon ablation was developed as a new treatment for pulmonary vein (PV) isolation and has demonstrated high procedural success and comforting long-term clinical outcome. However, some improvements are necessary for real-time visualization of PV signals that appeared important to increase the efficacy and reduce ineffective cryoapplications. We report, for the first time, a cryoablation procedure using the fourth-generation cryoballoon, describing betterment in vein signal recording and acute procedural success.</p>
Dataset related to the article "Cryoballoon or radiofrequency ablation? Alternating technique for repeat procedures in patients with atrial fibrillation"
<p>This record contains raw data related to the article "Cryoballoon or radiofrequency ablation? Alternating technique for repeat procedures in patients with atrial fibrillation".</p> <p> </p> <p><strong>Abstract</strong></p> <p><strong>Background: </strong>Which technique is better for repeat ablation in patients with atrial fibrillation (AF) remains unclear. The aim of the study was to compare long-term efficacy of repeat ablation using the alternative technique for the first redo ablation procedure: (a) cryoballoon (CB) re-ablation after a failed index pulmonary vein isolation (PVI) with radiofrequency (RF) ablation, RF-then-CB group or (b) RF repeat ablation following a failed CB ablation, CB-then-RF group.</p> <p><strong>Methods: </strong>Within the 1STOP Italian Project, consecutive patients undergoing repeat ablation with a different technique from the index procedure were included.</p> <p><strong>Results: </strong>We studied 474 patients, 349 in RF-then-CB and 125 in CB-then-RF group. Less women (21% vs 30%; P = .041), more persistent AF (33% vs 22%; P = .015), longer duration of AF (60 vs 31 months; P < .001), and more hypertension (50% vs 36%; P = .007) were observed in the RF-then-CB cohort as compared with the CB-then-RF group. The number of reconnected PVs was 3.7 ± 0.7 and 1.4 + 1.3 in RF-then-CB and CB-then-RF group, respectively (P < .001). During the follow-up, significantly less AF recurrence occurred in the CB-then-RF group (22% vs 8%, HR = 0.46; 95% CI: 0.24-0.92; P = .025). Cohort designation was the only independent predictor of AF recurrence.</p> <p><strong>Conclusion: </strong>Alternation of energy source for repeat ablation was safe and effective, regardless the energy used first. However, patients initially treated with CB PVI undergoing repeat ablation with RF current had less AF recurrence at long-term follow-up as compared with those originally treated by RF ablation receiving a CB repeat ablation.</p>
Dataset related to the article "Safety and Efficacy of Cryoballoon Ablation of Atrial Fibrillation in relation to the Patients' Age: Results from a Large Real-World Multicenter Observational Project"
<p>This record contains raw data related to the article "Safety and Efficacy of Cryoballoon Ablation of Atrial Fibrillation in relation to the Patients' Age: Results from a Large Real-World Multicenter Observational Project"</p> <p> </p> <p><em><strong>Abstract</strong></em></p> <p><strong>Background: </strong>The real-world efficacy and safety of atrial fibrillation (AF) ablation in particularly young and elderly patients are still under debate. The aim of the analysis was to investigate the effect of age on the efficacy and safety of cryoballoon ablation (CBA).</p> <p><strong>Methods: </strong>2,534 patients underwent pulmonary vein isolation (PVI) by way of CBA for paroxysmal or persistent drug-resistant and symptomatic AF. The population was divided into age quartiles for evaluation, including (1) <53 years, (2) ≥53 and <61 years, (3) ≥61 and <67 years, and (4) ≥67 years. Furthermore, outcomes were analyzed in patients <41 years, ≥41 and ≤74, and >74 years old. Procedural data and complications were collected, and atrial fibrillation recurrences were evaluated during follow-up.</p> <p><strong>Results: </strong>Procedural-related complications (4.1%) were similar in the four subgroups according to age. At the 12-month follow-up, freedom from AF recurrence was 79.2%, 77.4%, 76.8%, and 75.2% (<em>p</em>=0.21), respectively (with increasing age). At 24-month follow-up, similar incidences of AF recurrence were observed in the four subgroups. When the sample was arbitrarily divided into the three age groups, a higher rate of recurrence was observed in older patients with regard to long-term follow-up (freedom from AF recurrence was 71.8% and 40.9%, respectively, at 12 and 24-month follow-up). In the univariate and multivariate analysis, age did not result in a significant predictor of AF recurrence during follow-up; however, a trend toward higher AF recurrences rates in patients ≥67 years was observed.</p> <p><strong>Conclusion: </strong>The data demonstrated a high degree of safety during CBA across all patient ages. Procedural performance and complications were similar between different ages; AF recurrences seem to be more frequent in patients over 74 years.</p>
Dataset related to the article "Etiology and Outcome of Catheter Ablation in Patients With Onset of Atrial Fibrillation <45 Years of Age"
<p>This record contains raw data related to the article "Etiology and Outcome of Catheter Ablation in Patients With Onset of Atrial Fibrillation <45 Years of Age".</p> <p> </p> <p><em><strong>Abstract</strong></em></p> <p>Etiologic factors and long-term outcomes of catheter ablation of atrial fibrillation (AF) in young patients have not been well characterized. This study aimed to analyze the etiologic factors and outcomes of pulmonary vein isolation (PVI) in patients with young-onset AF (young-AF, defined as having first documented episode <45 years). Consecutive patients with young-AF undergoing PVI (n = 197) in 2 academic centers were enrolled and followed for 36.1 ± 24.5 months. A control group of patients with AF onset ≥45 years (n = 554) was included. The most frequent risk factors in young-AF were intensive exercise (25%), moderate-to-heavy alcohol consumption (23%), and familial AF (22%). Compared with patients with AF onset ≥45-year, patients with young-AF were more often men (82% vs 66%, p <0.001), had more frequently paroxysmal AF (81% vs 60%, p <0.001), had less left atrial dilatation (40.9 ± 6.2 mm vs 44.2 ± 7.2 mm, p <0.001), and had lower 4-year recurrence rate after last PVI procedure (22% vs 45%, p <0.001). In young-AF, structural heart disease (SHD) was the only independent predictor of recurrence. Patients with young-AF selected to undergo cryoballoon (CB) ablation were younger (35.0 ± 7.7 vs 36.6 ± 6.7 years, p = 0.035) and had less persistent AF (6% vs 24%, p = 0.004) and coronary artery disease (2% vs 7%, p = 0.02) compared with radiofrequency ablation. After excluding patients with persistent AF and SHD, there was no difference in single procedural success between radiofrequency or CB PVI (27% vs 17%, p = 0.11). In conclusion, patients with young-AF have diverse etiologies and high single and multiprocedural PVI successes. SHD is the only independent predictor of recurrence. In patients with young-AF, there is a selection bias for CB ablation.</p>
Dataset related to the article "Cryoablation for pulmonary veins isolation in obese patients with atrial fibrillation compared to nonobese patients"
<p>This record contains raw data related to the article "Cryoablation for pulmonary veins isolation in obese patients with atrial fibrillation compared to nonobese patients"</p> <p><em><strong>Abstract</strong></em></p> <p><strong>Background: </strong>Pulmonary veins isolation (PVI) by cryoballoon (CB) ablation is marginally represented in clinical studies in obese patients. The aim of this analysis was to evaluate the safety and efficacy of CB-PVI in a large cohort of overweight and obese patients from the 1STOP project.</p> <p><strong>Methods: </strong>From 2012 to 2018, 2048 patients with atrial fibrillation (AF) (70% male, 59 ± 11 years; 75% paroxysmal AF) underwent index CB-PVI. The patient data were separated into three cohorts for statistical evaluation, including: normal weight (body mass index [BMI] < 25 kg/m<sup>2</sup> ), overweight (BMI = 25-30 kg/m<sup>2</sup> ), and obese patients (BMI > 30 kg/m<sup>2</sup> ).</p> <p><strong>Results: </strong>Out of 2048 patients, 693 (34%) patients had a BMI < 25 and were deemed as normal. There were 944 (46%) patients categorized as overweight (BMI = 25-30) and 411 (20%) as obese (BMI > 30). Overweight or obese patients were more often in persistent AF, had more frequently hypertension and diabetes, had higher CHA<sub>2</sub> DS<sub>2</sub> -VASc score, and had a number of failed antiarrhythmic drug (AAD). Periprocedural complication rates were similar among the three cohorts. The 12-month freedom from AF recurrence was 76.4% in the normal BMI group as compared to 79.2% in the overweight and 73.5% in the obese group (p = .35). However, 48% of overweight patients were on AAD treatment during the follow-up. By multivariate analysis, BMI was not a predictor for AF recurrence following the index CB-PVI.</p> <p><strong>Conclusion: </strong>CB-PVI in obese patients is a safe procedure. Increased BMI (either moderate or severe) does not seem to be associated with a worse outcome or to a different rate of AAD discontinuation at 12 months.</p> <p> </p> <p> </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.